Last updated on August 2019

A Study to Evaluate the Safety Tolerability Pharmacokinetics (PK) Pharmacodynamics (PD) and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma


Brief description of study

This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).

Detailed Study Description

In the Phase Ia part of the study, tiragolumab is administered as a single agent in participants with R/R MM or R/R NHL.

In the Phase Ib part of the study, tiragolumab is administered in combination with daratumumab in participants with R/R MM or with rituximab in participants with R/R NHL for whom combination therapy is considered an acceptable treatment option.

Clinical Study Identifier: NCT04045028

Find a site near you

Start Over

University of Pennsylvania; School of Medicine

Philadelphia, PA United States
8.05miles
  Connect »